NEJM June 2028 Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection

This Week In Medicine · Jul 1, 2026 · 1m

This text details a medical breakthrough involving bepirovirsen, an innovative antisense oligonucleotide designed to treat chronic hepatitis B. Through two large-scale clinical trials, researchers tested the drug's ability to achieve a functional cure, which allows patients to maintain low viral levels and clear specific antigens even after stopping standard medication. The findings reveal that roughly one-fifth of participants reached this milestone, marking a statistically significant improvement over those receiving a placebo. While the treatment showed promise in suppressing the virus…